GB873526A - Fluid compositions comprising (acetyl-salicylic acid)-anhydride - Google Patents
Fluid compositions comprising (acetyl-salicylic acid)-anhydrideInfo
- Publication number
- GB873526A GB873526A GB23544/58A GB2354458A GB873526A GB 873526 A GB873526 A GB 873526A GB 23544/58 A GB23544/58 A GB 23544/58A GB 2354458 A GB2354458 A GB 2354458A GB 873526 A GB873526 A GB 873526A
- Authority
- GB
- United Kingdom
- Prior art keywords
- glycerine
- ingredients
- anhydride
- propylene glycol
- acetyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- OAWXYINGQXLWOE-UHFFFAOYSA-N (2-acetyloxybenzoyl) 2-acetyloxybenzoate Chemical compound CC(=O)OC1=CC=CC=C1C(=O)OC(=O)C1=CC=CC=C1OC(C)=O OAWXYINGQXLWOE-UHFFFAOYSA-N 0.000 title abstract 2
- 239000012530 fluid Substances 0.000 title abstract 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract 9
- 235000011187 glycerol Nutrition 0.000 abstract 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 abstract 4
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 abstract 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 abstract 4
- CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 abstract 4
- 239000004615 ingredient Substances 0.000 abstract 3
- 239000002245 particle Substances 0.000 abstract 3
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 abstract 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 abstract 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 abstract 2
- 229960001948 caffeine Drugs 0.000 abstract 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 abstract 2
- 239000003240 coconut oil Substances 0.000 abstract 2
- 235000019864 coconut oil Nutrition 0.000 abstract 2
- 229960004126 codeine Drugs 0.000 abstract 2
- 235000012343 cottonseed oil Nutrition 0.000 abstract 2
- 239000002385 cottonseed oil Substances 0.000 abstract 2
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 abstract 2
- 229960000890 hydrocortisone Drugs 0.000 abstract 2
- 239000007788 liquid Substances 0.000 abstract 2
- 229960003893 phenacetin Drugs 0.000 abstract 2
- 239000000725 suspension Substances 0.000 abstract 2
- 239000003981 vehicle Substances 0.000 abstract 2
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 abstract 1
- IVQOFBKHQCTVQV-UHFFFAOYSA-N 2-hydroxy-2,2-diphenylacetic acid 2-(diethylamino)ethyl ester Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCCN(CC)CC)C1=CC=CC=C1 IVQOFBKHQCTVQV-UHFFFAOYSA-N 0.000 abstract 1
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical class NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 abstract 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 abstract 1
- 244000060011 Cocos nucifera Species 0.000 abstract 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 abstract 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 abstract 1
- 239000002202 Polyethylene glycol Substances 0.000 abstract 1
- SKZKKFZAGNVIMN-UHFFFAOYSA-N Salicilamide Chemical compound NC(=O)C1=CC=CC=C1O SKZKKFZAGNVIMN-UHFFFAOYSA-N 0.000 abstract 1
- 239000004098 Tetracycline Substances 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 150000008064 anhydrides Chemical class 0.000 abstract 1
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 230000001387 anti-histamine Effects 0.000 abstract 1
- 229940088710 antibiotic agent Drugs 0.000 abstract 1
- 229940125715 antihistaminic agent Drugs 0.000 abstract 1
- 239000000739 antihistaminic agent Substances 0.000 abstract 1
- 229960001498 benactyzine Drugs 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000000084 colloidal system Substances 0.000 abstract 1
- 229960004544 cortisone Drugs 0.000 abstract 1
- 239000003974 emollient agent Substances 0.000 abstract 1
- 235000019441 ethanol Nutrition 0.000 abstract 1
- 239000000796 flavoring agent Substances 0.000 abstract 1
- 238000003801 milling Methods 0.000 abstract 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 abstract 1
- 229920001515 polyalkylene glycol Polymers 0.000 abstract 1
- 229920001223 polyethylene glycol Polymers 0.000 abstract 1
- 235000013772 propylene glycol Nutrition 0.000 abstract 1
- 238000010298 pulverizing process Methods 0.000 abstract 1
- 229960000581 salicylamide Drugs 0.000 abstract 1
- 229940125723 sedative agent Drugs 0.000 abstract 1
- 239000000932 sedative agent Substances 0.000 abstract 1
- 239000008159 sesame oil Substances 0.000 abstract 1
- 235000011803 sesame oil Nutrition 0.000 abstract 1
- RNVYQYLELCKWAN-UHFFFAOYSA-N solketal Chemical compound CC1(C)OCC(CO)O1 RNVYQYLELCKWAN-UHFFFAOYSA-N 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
- 229960002180 tetracycline Drugs 0.000 abstract 1
- 229930101283 tetracycline Natural products 0.000 abstract 1
- 235000019364 tetracycline Nutrition 0.000 abstract 1
- 150000003522 tetracyclines Chemical class 0.000 abstract 1
- 239000003204 tranquilizing agent Substances 0.000 abstract 1
- 230000002936 tranquilizing effect Effects 0.000 abstract 1
- 235000015112 vegetable and seed oil Nutrition 0.000 abstract 1
- 239000008158 vegetable oil Substances 0.000 abstract 1
- 239000011782 vitamin Substances 0.000 abstract 1
- 229940088594 vitamin Drugs 0.000 abstract 1
- 229930003231 vitamin Natural products 0.000 abstract 1
- 235000013343 vitamin Nutrition 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
- A61K31/621—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate having the hydroxy group in position 2 esterified, e.g. benorylate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
A stable, fluid composition for oral use comprises (acetylsalicylic acid)-anhydride and a liquid carrier which may be glycerine, propylene glycol, a liquid polyalkylene glycol, a vegetable oil, e.g. coconut, cottonseed or sesame oils, 2,2-dimethyl-4-oxymethyl-1,3-dioxolane, N,N-dimethyl acetamide (preferred for solutions) or mixtures thereof which are miscible with each other and compatible with other ingredients. Anhydrous ethanol may also be present when compatible, e.g. with glycerine or propylene glycol. The water content of the vehicle should not exceed 5% by weight and preferably should not be more than 1%. Additional active ingredients, for example, acetophenetidin, caffeine, codeine, salicylamide, N - acetyl - p - aminophenol, cortisone, hydrocortisone or its derivatives, tranquilizers, sedatives, antihistaminics, anti-ussive agents, antibiotics and vitamins, especially ascorbic, pantothenic and p-aminobenzoic acids, may also be present. Other ingredients, for example, sweetening, suspending, demulcent, flavouring and surface-active agents, may also be added. The anhydride and other ingredients may be in particles of reduced size produced, for example, by milling to give particles of about 10 to 100 microns in size or by jet-pulverizing e.g. air-micronizing to give particles of under 10 microns. For suspensions, for which glycerine is the preferred vehicle, uniformity of the product may be assured, e.g. by passage through a colloid mill or homogenizing equipment. Examples given are suspensions in glycerine, glycerine and ethanol, polyethylene glycol, propylene glycol, coconut oil and cottonseed oil comprising also acetophenetidin, caffeine, codeine, hydrocortisone, phenobarbitol, benactyzine, tetracycline and b -ortho-methoxyphenylisopropyl methylamine and of a solution in N,N-dimethylacetamide.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US873526XA | 1957-08-14 | 1957-08-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB873526A true GB873526A (en) | 1961-07-26 |
Family
ID=22204677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB23544/58A Expired GB873526A (en) | 1957-08-14 | 1958-07-22 | Fluid compositions comprising (acetyl-salicylic acid)-anhydride |
Country Status (1)
| Country | Link |
|---|---|
| GB (1) | GB873526A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0856310A3 (en) * | 1997-02-04 | 2000-01-19 | Senju Pharmaceutical Co., Ltd. | Method for stabilizing acriylcarboxylic acid, stabilizer thereof and aqueous solution containing stabilized acrylcarboxylic acid |
| GB2533669A (en) * | 2014-12-23 | 2016-06-29 | Innovate Pharmaceuticals Ltd | Salicylate compound composition |
| US10010612B2 (en) | 2007-05-25 | 2018-07-03 | Indivior Uk Limited | Sustained delivery formulations of risperidone compounds |
| US10022367B2 (en) | 2014-03-10 | 2018-07-17 | Indivior Uk Limited | Sustained-release buprenorphine solutions |
| US10058554B2 (en) | 2005-09-30 | 2018-08-28 | Indivior Uk Limited | Sustained release small molecule drug formulation |
| US10172849B2 (en) | 2010-06-08 | 2019-01-08 | Indivior Uk Limited | Compositions comprising buprenorphine |
| US10198218B2 (en) | 2010-06-08 | 2019-02-05 | Indivior Uk Limited | Injectable flowable composition comprising buprenorphine |
-
1958
- 1958-07-22 GB GB23544/58A patent/GB873526A/en not_active Expired
Cited By (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6274592B1 (en) | 1997-02-04 | 2001-08-14 | Senju Pharmaceutical Co., Ltd. | Method for stabilizing arylcarboxylic acid, stabilizer thereof and aqueous solution containing stabilized arylcarboxylic acid |
| EP1389469A1 (en) * | 1997-02-04 | 2004-02-18 | Senju Pharmaceutical Co., Ltd. | Method for stabilizing arylcarboxylic acid, stabilizer thereof and aqueous solution containing stabilized arylcarboxylic acid |
| US7320985B2 (en) | 1997-02-04 | 2008-01-22 | Senju Pharmaceutical Co., Ltd. | Method for stabilizing arylcarboxylic acid, stabilizer thereof and aqueous solution containing stabilized arylcarboxylic acid |
| EP0856310A3 (en) * | 1997-02-04 | 2000-01-19 | Senju Pharmaceutical Co., Ltd. | Method for stabilizing acriylcarboxylic acid, stabilizer thereof and aqueous solution containing stabilized acrylcarboxylic acid |
| US11110093B2 (en) | 2005-09-30 | 2021-09-07 | Indivior Uk Limited | Sustained release small molecule drug formulation |
| US10058554B2 (en) | 2005-09-30 | 2018-08-28 | Indivior Uk Limited | Sustained release small molecule drug formulation |
| US10376590B2 (en) | 2007-05-25 | 2019-08-13 | Indivior Uk Limited | Sustained delivery formulations of risperidone compound |
| US11712475B2 (en) | 2007-05-25 | 2023-08-01 | Indivior Uk Limited | Sustained delivery formulations of risperidone compound |
| US11013809B2 (en) | 2007-05-25 | 2021-05-25 | Indivior Uk Limited | Sustained delivery formulations of risperidone compound |
| US10010612B2 (en) | 2007-05-25 | 2018-07-03 | Indivior Uk Limited | Sustained delivery formulations of risperidone compounds |
| US10592168B1 (en) | 2010-06-08 | 2020-03-17 | Indivior Uk Limited | Injectable flowable composition comprising buprenorphine |
| US10198218B2 (en) | 2010-06-08 | 2019-02-05 | Indivior Uk Limited | Injectable flowable composition comprising buprenorphine |
| US10172849B2 (en) | 2010-06-08 | 2019-01-08 | Indivior Uk Limited | Compositions comprising buprenorphine |
| US10558394B2 (en) | 2010-06-08 | 2020-02-11 | Indivior Uk Limited | Injectable flowable composition comprising buprenorphine |
| US10517864B2 (en) | 2014-03-10 | 2019-12-31 | Indivior Uk Limited | Sustained-release buprenorphine solutions |
| US10022367B2 (en) | 2014-03-10 | 2018-07-17 | Indivior Uk Limited | Sustained-release buprenorphine solutions |
| GB2533669B (en) * | 2014-12-23 | 2016-12-14 | Innovate Pharmaceuticals Ltd | Salicylate compound composition |
| AU2015370673B2 (en) * | 2014-12-23 | 2021-06-03 | Innovate Pharmaceuticals Limited | Salicylate compound composition |
| WO2016102959A1 (en) * | 2014-12-23 | 2016-06-30 | Innovate Pharmaceuticals Limited | Salicylate compound composition |
| US11129837B2 (en) | 2014-12-23 | 2021-09-28 | Innovate Pharmaceuticals Limited | Salicylate compound composition |
| GB2533669A (en) * | 2014-12-23 | 2016-06-29 | Innovate Pharmaceuticals Ltd | Salicylate compound composition |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR900015741A (en) | Pharmaceutical composition | |
| US3981996A (en) | Pharmaceutical skin compositions | |
| RU2224505C2 (en) | Utilizing nanodispersions in compositions for pharmaceutical application | |
| US3636200A (en) | Pharmaceutical suspension | |
| KR840006437A (en) | Method of Preparation of Formulation for Oral Antibiotic Administration | |
| JPS5637040A (en) | Oil-in-polyhydric alcohol type emulsifying composition | |
| ES8800039A1 (en) | Pharmaceutical composition. | |
| ES350165A1 (en) | Liquid dentifrice containing powdered abrasive | |
| IE34751L (en) | Liquid detergent compositions | |
| GB873526A (en) | Fluid compositions comprising (acetyl-salicylic acid)-anhydride | |
| JPS5659710A (en) | Preventive and remedy for psoriasis | |
| ES2171525T3 (en) | PHARMACEUTICAL COMPOSITIONS FOR TOPICAL USE CONTAINING PROPIONIC ACID (S) -2- (4-ISOBUTILFENIL). | |
| KR910016333A (en) | Process for the preparation of the pyroxicam / cyclodextrin complex, the product obtained thereby and the pharmaceutical composition thereof | |
| LV11818A (en) | A new pharmaceutical composition for the preparation of a stable powder-shaped form | |
| IE35811L (en) | Triazolo diazepines | |
| IT1140529B (en) | COMPOSITIONS TO BE USED AS COSMETICS AND PROCEDURE FOR THE PREPARATION OF THEIR ACTIVE INGREDIENTS | |
| US2773835A (en) | Liquid shampoo composition | |
| GB1042855A (en) | Polystyrene fibres | |
| US3024165A (en) | Effervescent acetyl-salicylic acid tablet | |
| SE8304062L (en) | NEW DICLORATED DERIVATIVES OF THE 16ALFA-METHYL PREGNANCY SERIES, PREPARATION thereof, USE THEREOF AS MEDICINAL PRODUCTS AND COMPOSITIONS CONTAINING THEM | |
| AR017215A1 (en) | COMPOSITIONS CONTAINING NITRIC OXIDE GENERATORS AND USE OF SUCH GENERATORS FOR THE PREPARATION OF A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF DRY EYE DISORDERS | |
| ES396666A1 (en) | Toothpaste composition | |
| JPS5731614A (en) | Lipid improver | |
| GR32930B (en) | DETERGENT COMPOSITION. | |
| JPS54117022A (en) | Steroid ointment |